Chiral modified silica monoliths have become well established stationary phases for high performance liquid chromatography (HPLC) [1, 2]. Native and derivatized cyclodextrins have been used successfully in both chromatographic and electrophoretic techniques due to their high enantiorecognition abilities as well as their low cost associated with good availability [3, 4].
A new environmentally friendly format for chiral separation was investigated using nano-high performance liquid chromatography (nHPLC) with silica bonded chiral β-cyclodextrin based stationary phase. Fifty six compounds of different pharmaceutical classes (β-blockers, NSAIDs, antifungals, dopamine antagonists, peptides and catecholamines) were screened on the newly developed stationary phase. Baseline separation for twelve compounds (alprenolol, arterenol, bufuralol, carbuterol, celiprolol, desmethyl cizolertine, metoprolol, miconazole, methoxymandelic acid, cizolirtine, normetanephrine and eticlopride) was achieved under reversed phase conditions. Separation (α) and resolution (RS) factors range between 1.62-2.61 and 1.36-2.44 respectively. The new stationary phase provides a promising enantiomeric separation for different classes of pharmaceuticals and expands the area of chiral separation to embrace benign and mild reversed phase conditions.